Topics

Posted 9/13/2023, 10:30:00 AM

Moderna's mRNA Flu and RSV Vaccines Show Promise in Latest Trial Data

Moderna's experimental mRNA flu shot generated a stronger immune response against flu strains than an approved vaccine in a Phase 3 study.
Moderna is racing Pfizer to bring mRNA technology to flu vaccines to better target circulating strains.
Moderna expects an FDA decision on its mRNA RSV vaccine for adults 60+ by April.
Previous version of Moderna's flu vaccine didn't generate response against flu B strains; new version did.
Study focused on immune response over efficacy data; Moderna stopped separate efficacy study that didn't have enough cases.

cnn.com

Relevant topic timeline:

8/18/2023

Fall COVID shots will boost protection against latest subvariants, Moderna says

Main topic: Moderna's updated COVID-19 vaccine shows efficacy against omicron subvariants. Key points: 1. Moderna's updated COVID-19 vaccine boosts neutralizing antibodies against omicron subvariants EG.5 and FL.1.5.1. 2. The booster shot is expected to be authorized and rolled out soon. 3. The preliminary trial data aims to reassure concerns about the vaccine's effectiveness against current variants.

8/21/2023

Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market

Moderna's stock surged after the biotech company partnered with Carsgen to study a new cancer vaccine regimen using mRNA technology, giving Moderna a second opportunity in the field of cancer vaccines.

9/6/2023

Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial

Moderna's updated Covid vaccine has shown a strong immune response against the highly mutated omicron variant BA.2.86, suggesting that the vaccine will still be effective against newer variants of the virus.

9/12/2023

African Scientists Make Progress on Homegrown mRNA Vaccines, But Face Delays on COVID Trials

Afrigen Biologics and Vaccines, a South African pharmaceutical firm, has made significant progress in developing an mRNA vaccine against COVID-19, potentially expanding access to vaccines globally and enabling lower-income countries to produce their own mRNA vaccines.

9/13/2023

Moderna's New Flu Vaccine Shows Stronger Immune Response Than Traditional Shots in Late-Stage Trial

Moderna's flu vaccine has demonstrated a stronger immune response against all strains of the influenza virus compared to traditional flu shots, potentially allowing the company to file for accelerated approval in the US by year-end and launch the vaccine for the 2024/2025 season, while also scaling down its COVID-19 vaccine manufacturing to meet lower post-pandemic demand.

9/14/2023

Moderna Looks Beyond Covid, Plans 15 New Products Including Flu Vaccine

Moderna CEO Stéphane Bancel asserts that the positive data on the company's influenza vaccine and their plans to launch 15 products in the next five years demonstrate that they are not solely a Covid vaccine company.

10/4/2023

Moderna's Combination Flu/COVID Vaccine Shows Promise in Early Trial

Moderna has announced positive results from a Phase 1/2 clinical trial of its combination vaccine, mRNA-1083, against both influenza and Covid-19, revealing strong immune responses and safety, with a Phase 3 trial planned for this year for adults aged 50 and older.

10/4/2023

Moderna Developing New Fridge-Stable Flu and COVID Vaccines in Pre-Filled Syringes

Moderna is developing new refrigerator-stable vaccines that are easier to administer and do not require the same freezing conditions as previous COVID-19 vaccines, making them more accessible for use globally.

10/5/2023

FDA authorizes Novavax COVID-19 vaccine, offering new protein-based option for unvaccinated

The FDA has authorized a new Novavax vaccine that uses a protein targeting method to protect against the Omicron variant, providing an alternative option to the mRNA vaccines by Moderna and Pfizer.

10/5/2023

Moderna to Test Flu-COVID Vaccine Combo in Late-Stage Trials, Aiming for 2025 Approval

Moderna plans to advance a novel vaccine design targeting both flu and COVID-19 into its final stage of development, aiming to simplify annual vaccinations and increase vaccine uptake, with hopes of regulatory approval by 2025.

10/6/2023

Moderna Leads Race for Combined Flu/COVID Vaccine, Aiming for 2025 Launch

Moderna, Pfizer, and Novavax are racing to develop a combined flu and coronavirus vaccine, with Moderna reportedly jumping ahead with promising results from its phase 1/2 study.

Topics

Posted 9/13/2023, 10:30:00 AM

Moderna's mRNA Flu and RSV Vaccines Show Promise in Latest Trial Data

Moderna's experimental mRNA flu shot generated a stronger immune response against flu strains than an approved vaccine in a Phase 3 study.
Moderna is racing Pfizer to bring mRNA technology to flu vaccines to better target circulating strains.
Moderna expects an FDA decision on its mRNA RSV vaccine for adults 60+ by April.
Previous version of Moderna's flu vaccine didn't generate response against flu B strains; new version did.
Study focused on immune response over efficacy data; Moderna stopped separate efficacy study that didn't have enough cases.

cnn.com

Relevant topic timeline:

8/18/2023

Fall COVID shots will boost protection against latest subvariants, Moderna says

8/21/2023

Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market

9/6/2023

Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial

9/12/2023

African Scientists Make Progress on Homegrown mRNA Vaccines, But Face Delays on COVID Trials

9/13/2023

Moderna's New Flu Vaccine Shows Stronger Immune Response Than Traditional Shots in Late-Stage Trial

9/14/2023

Moderna Looks Beyond Covid, Plans 15 New Products Including Flu Vaccine

10/4/2023

Moderna's Combination Flu/COVID Vaccine Shows Promise in Early Trial

10/4/2023

Moderna Developing New Fridge-Stable Flu and COVID Vaccines in Pre-Filled Syringes

10/5/2023

FDA authorizes Novavax COVID-19 vaccine, offering new protein-based option for unvaccinated

The FDA has authorized a new Novavax vaccine that uses a protein targeting method to protect against the Omicron variant, providing an alternative option to the mRNA vaccines by Moderna and Pfizer.

10/5/2023

Moderna to Test Flu-COVID Vaccine Combo in Late-Stage Trials, Aiming for 2025 Approval

10/6/2023

Moderna Leads Race for Combined Flu/COVID Vaccine, Aiming for 2025 Launch

Moderna, Pfizer, and Novavax are racing to develop a combined flu and coronavirus vaccine, with Moderna reportedly jumping ahead with promising results from its phase 1/2 study.